Atsuko Tsukimoto, Ryuichi Sugiyama, Makoto Abe, Hironori Nishitsuji, Yuko Shimizu, Kunitada Shimotohno, Gota Kawai, Hiroshi Takaku
Antiviral research 2015 MayPrevious studies have demonstrated that cyclopentenone prostaglandins (cyPGs) inhibit the replication of a wide variety of DNA and RNA viruses in different mammalian cell types. We investigated a new role for prostaglandin A1 (PGA1) in the inhibition of hepatitis C virus (HCV)-IRES-mediated translation. PGA1 exhibited dose-dependent inhibitory effects on HCV translation in HCV replicon cells. Furthermore, repetitive PGA1 treatment demonstrated the potential to safely induce the suppression of HCV translation. We also validated a new role for PGA1 in the inhibition of HCV-IRES-mediated translation by targeting cellular translation factors, including the small ribosomal subunit (40S) and eukaryotic initiation factors (eIFs). In pull-down assays, biotinylated PGA1 co-precipitated with the entire HCV IRES RNA/eIF3-40S subunit complex. Moreover, the interactions between PGA1 and the elongation factors and ribosomal subunit were dependent upon HCV IRES RNA binding, and the PGA1/HCV IRES RNA/eIF3-40S subunit complex inhibited HCV-IRES-mediated translation. The novel mechanism revealed in this study may aid in the search for more effective anti-HCV drugs. Copyright © 2015 Elsevier B.V. All rights reserved.
Atsuko Tsukimoto, Ryuichi Sugiyama, Makoto Abe, Hironori Nishitsuji, Yuko Shimizu, Kunitada Shimotohno, Gota Kawai, Hiroshi Takaku. A new role for PGA1 in inhibiting hepatitis C virus-IRES-mediated translation by targeting viral translation factors. Antiviral research. 2015 May;117:1-9
PMID: 25666760
View Full Text